Quality Measure Implementation Guide
This page is part of the Quality Measure STU2 for FHIR R4 Implementation Guide (v0.1.0: STU 1 Ballot 1) based on FHIR R3. The current version which supercedes this version is 3.0.0. For a full list of available versions, see the Directory of published versions 
<Measure xmlns="http://hl7.org/fhir"> <id value="measure-exm125-FHIR"/> <meta> <versionId value="3"/> <lastUpdated value="2019-03-12T11:08:02.539-06:00"/> <profile value="http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/proportion-measure-cqfm"/> </meta> <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"><table class="grid dict"><tr style="vertical-align: top;"><th scope="row"><b>Id: </b></th><td style="padding-left: 25px; padding-right: 25px;">Measure/measure-exm125-FHIR</td></tr><tr style="vertical-align: top;"><th rowspan="1" scope="row"><b>Type: </b></th><td style="padding-left: 25px; padding-right: 25px;"><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-type</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>process</span></span></span></span></td></tr><tr style="vertical-align: top;"><th rowspan="2" scope="row"><b>Identifier: </b></th><td style="padding-left: 25px; padding-right: 25px;"><b>system: </b><span>http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms</span><br/><b>value: </b><span>146</span></td></tr><tr style="vertical-align: top;"><td style="padding-left: 25px; padding-right: 25px;"><b>system: </b><span>http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/nqf</span><br/><b>value: </b><span>0002</span></td></tr><tr style="vertical-align: top;"><th scope="row"><b>Title: </b></th><td style="padding-left: 25px; padding-right: 25px;">Breast Cancer Screening</td></tr><tr style="vertical-align: top;"><th scope="row"><b>Status: </b></th><td style="padding-left: 25px; padding-right: 25px;">active</td></tr><tr style="vertical-align: top;"><th scope="row"><b>Description: </b></th><td style="padding-left: 25px; padding-right: 25px;">Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer</td></tr><tr style="vertical-align: top;"><th scope="row"><b>Purpose: </b></th><td style="padding-left: 25px; padding-right: 25px;">Women 51-74 years of age with a visit during the measurement period</td></tr><tr style="vertical-align: top;"><th rowspan="1" scope="row"><b>Use Context: </b></th><td style="padding-left: 25px; padding-right: 25px;"><p style="padding-left: 25px; margin-bottom: 5px;"><b>code: </b><span>program</span></p><p style="padding-left: 25px; margin-bottom: 5px;"><b>value: </b><br/><span><span style="padding-left: 25px;"><b>text: </b><span>eligibile-provider</span></span></span></p></td></tr><tr style="vertical-align: top;"><th rowspan="1" scope="row"><b>Topic: </b></th><td style="padding-right: 25px;"><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://loinc.org</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>57024-2</span><br/></span><span style="padding-left: 25px;"><b>display: </b><span>Health Quality Measure Document</span></span></span></span></td></tr><tr style="vertical-align: top;"><th rowspan="1" scope="row"><b>Contributor: </b></th><td style="padding-left: 25px; padding-right: 25px;"><b><span>author</span>: </b><span>National Committee for Quality Assurance</span></td></tr><tr style="vertical-align: top;"><th rowspan="5" scope="row"><b>Related: </b></th><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>type: </b><span>citation</span></p><p style="margin-bottom: 5px;"><b>citation: </b><br/><span>American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society.</span></p></td></tr><tr style="vertical-align: top;"><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>type: </b><span>citation</span></p><p style="margin-bottom: 5px;"><b>citation: </b><br/><span>National Cancer Institute. 2010. "Breast Cancer Screening." http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional</span></p></td></tr><tr style="vertical-align: top;"><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>type: </b><span>citation</span></p><p style="margin-bottom: 5px;"><b>citation: </b><br/><span>National Business Group on Health. 2011. Pathways to Managing Cancer in the Workplace. Washington: National Business Group on Health.</span></p></td></tr><tr style="vertical-align: top;"><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>type: </b><span>citation</span></p><p style="margin-bottom: 5px;"><b>citation: </b><br/><span>U.S. Preventive Services Task Force (USPSTF). 2009. 1) "Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement." 2) "December 2009 addendum." Ann Intern Med 151(10):716-726.</span></p></td></tr><tr style="vertical-align: top;"><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>type: </b><span>citation</span></p><p style="margin-bottom: 5px;"><b>citation: </b><br/><span>BreastCancer.org. 2012. U.S. Breast Cancer Statistics. www.breastcancer.org/symptoms/understand_bc/statistics.jsp</span></p></td></tr><tr style="vertical-align: top;"><th rowspan="1" scope="row"><b>Library: </b></th><td><p style="padding-left: 25px; padding-right: 25px;"><b>reference: </b><span>Library/library-exm125-FHIR</span></p></td></tr><tr><th scope="row"><b>Disclaimer: </b></th><td style="padding-left: 25px; padding-right: 25px;">The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.</td></tr><tr><th scope="row"><b>Scoring: </b></th><td style="padding-left: 25px; padding-right: 25px;"><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-scoring</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>proportion</span></span></span></span></td></tr><tr><th scope="row"><b>Rationale: </b></th><td style="padding-left: 25px; padding-right: 25px;">Breast cancer is one of the most common types of cancers, accounting for a quarter of all new cancer diagnoses for women in the U.S. (BreastCancer.Org, 2011). It ranks as the second leading cause of cancer-related mortality in women, accounting for nearly 40,000 estimated deaths in 2013 (American Cancer Society, 2011). <br> According to the National Cancer Institute's Surveillance Epidemiology and End Results program, the chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 30, it is one in 2,212. By age 40, the chances increase to one in 235, by age 50, it becomes one in 54, and, by age 60, it is one in 25. From 2004 to 2008, the median age at the time of breast cancer diagnosis was 61 years among adult women (Tangka et al, 2010). <br> In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits, and varying procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (Lavigne et al, 2008; Boykoff et al, 2009).</td></tr><tr><th scope="row"><b>Clinical Recommendation: </b></th><td style="padding-left: 25px; padding-right: 25px;">The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years (B recommendation). The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C recommendation). The Task Force concludes the evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I statement). <br> U.S. Preventive Services Task Force (2009) <br> Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. <br> Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. <br> Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE). <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.</td></tr><tr><th scope="row"><b>Guidance: </b></th><td style="padding-left: 25px; padding-right: 25px;">Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. <br> This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, MRIs or tomosynthesis (3D mammography), because they are not appropriate methods for primary breast cancer screening.</td></tr><tr style="vertical-align: top;"><th scope="row"><b>Group:</b></th><td><p style="padding-left: 25px; padding-right: 25px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>group-1</span><br/></span></p></td></tr><tr style="vertical-align: top;"><td colspan="2"><table style="margin-bottom: 5px; width: 100%"><tr style="vertical-align: top;"><th rowspan="4" scope="row" style="padding-left: 25px;"><b>Population:</b></th><td><p style="margin-bottom: 5px; padding-left: 25px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>initial-population-identifier</span><br/></span></p><p style="margin-bottom: 5px; padding-left: 25px;"><b>criteria: </b><span>Initial Population</span></p></td></tr><tr style="vertical-align: top;"><td><p style="margin-bottom: 5px; padding-left: 25px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>numerator-identifier</span><br/></span></p><p style="margin-bottom: 5px; padding-left: 25px;"><b>criteria: </b><span>Numerator</span></p></td></tr><tr style="vertical-align: top;"><td><p style="margin-bottom: 5px; padding-left: 25px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>denominator-identifier</span><br/></span></p><p style="margin-bottom: 5px; padding-left: 25px;"><b>criteria: </b><span>Denominator</span></p></td></tr><tr style="vertical-align: top;"><td><p style="margin-bottom: 5px; padding-left: 25px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>denominator-exclusions-identifier</span><br/></span></p><p style="margin-bottom: 5px; padding-left: 25px;"><b>criteria: </b><span>Denominator Exclusion</span></p></td></tr></table></td></tr><tr><th rowspan="4" scope="row"><b>Supplemental Data:</b></th><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>sde-ethnicity</span><br/></span></p><p style="margin-bottom: 5px;"><b>usage: </b><span><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style="margin-bottom: 5px;"><b>criteria: </b><span>SDE Ethnicity</span></p></td></tr><tr><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>sde-payer</span><br/></span></p><p style="margin-bottom: 5px;"><b>usage: </b><span><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style="margin-bottom: 5px;"><b>criteria: </b><span>SDE Payer</span></p></td></tr><tr><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>sde-race</span><br/></span></p><p style="margin-bottom: 5px;"><b>usage: </b><span><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style="margin-bottom: 5px;"><b>criteria: </b><span>SDE Race</span></p></td></tr><tr><td style="padding-left: 25px; padding-right: 25px;"><p style="margin-bottom: 5px;"><b>Identifier:</b><br/><span style="padding-left: 25px;"><b>value: </b><span>sde-sex</span><br/></span></p><p style="margin-bottom: 5px;"><b>usage: </b><span><span><br/><span><span style="padding-left: 25px;"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style="padding-left: 25px;"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style="margin-bottom: 5px;"><b>criteria: </b><span>SDE Sex</span></p></td></tr></table></div> </text> <extension url="http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/cqfm-populationBasis"> <valueCode value="boolean"/> </extension> <url value="http://hl7.org/fhir/us/cqfmeasures/Measure/measure-exm125-FHIR"/> <identifier> <use value="official"/> <system value="http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms"/> <value value="146"/> </identifier> <identifier> <use value="official"/> <system value="http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/nqf"/> <value value="0002"/> </identifier> <version value="6.2.000"/> <name value="EXM125"/> <title value="Breast Cancer Screening"/> <status value="active"/> <experimental value="true"/> <date value="2018-08-31"/> <publisher value="National Committee for Quality Assurance"/> <description value="Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer"/> <purpose value="Women 51-74 years of age with a visit during the measurement period"/> <approvalDate value="2016-01-01"/> <lastReviewDate value="2016-09-01"/> <effectivePeriod> <start value="2018-01-01"/> <end value="2018-12-31"/> </effectivePeriod> <useContext> <code> <code value="program"/> </code> <valueCodeableConcept> <text value="eligibile-provider"/> </valueCodeableConcept> </useContext> <jurisdiction> <coding> <system value="urn:iso:std:iso:3166"/> <code value="US"/> </coding> </jurisdiction> <topic> <coding> <system value="http://loinc.org"/> <code value="57024-2"/> <display value="Health Quality Measure Document"/> </coding> </topic> <contributor> <type value="author"/> <name value="National Committee for Quality Assurance"/> </contributor> <contact> <telecom> <system value="url"/> <value value="http://www.ncqa.org/"/> </telecom> </contact> <copyright value="This Physician Performance Measure (Measure) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). The Measure is copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. (C) 2012-2017 National Committee for Quality Assurance. All Rights Reserved. <br> Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications. <br> CPT(R) contained in the Measure specifications is copyright 2004-2016 American Medical Association. LOINC(R) copyright 2004-2016 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2016 International Health Terminology Standards Development Organisation. ICD-10 copyright 2016 World Health Organization. All Rights Reserved. <br> The American Hospital Association holds a copyright to the National Uniform Billing Committee (NUBC) codes contained in the measure specifications. The NUBC codes in the specifications are included with the permission of the AHA. The NUBC codes contained in the specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting Measure results or using Measure results for their internal quality improvement purposes. All other uses of the NUBC codes require a license from the AHA. Anyone desiring to use the NUBC codes in a commercial product to generate Measure results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@healthforum.com."/> <relatedArtifact> <type value="citation"/> <citation value="American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society."/> </relatedArtifact> <relatedArtifact> <type value="citation"/> <citation value="National Cancer Institute. 2010. "Breast Cancer Screening." http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional"/> </relatedArtifact> <relatedArtifact> <type value="citation"/> <citation value="National Business Group on Health. 2011. Pathways to Managing Cancer in the Workplace. Washington: National Business Group on Health."/> </relatedArtifact> <relatedArtifact> <type value="citation"/> <citation value="U.S. Preventive Services Task Force (USPSTF). 2009. 1) "Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement." 2) "December 2009 addendum." Ann Intern Med 151(10):716-726."/> </relatedArtifact> <relatedArtifact> <type value="citation"/> <citation value="BreastCancer.org. 2012. U.S. Breast Cancer Statistics. www.breastcancer.org/symptoms/understand_bc/statistics.jsp"/> </relatedArtifact> <library> <reference value="Library/library-exm125-FHIR"/> </library> <disclaimer value="The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND."/> <scoring> <coding> <system value="http://hl7.org/fhir/measure-scoring"/> <code value="proportion"/> </coding> </scoring> <type> <coding> <system value="http://hl7.org/fhir/measure-type"/> <code value="process"/> </coding> </type> <rationale value="Breast cancer is one of the most common types of cancers, accounting for a quarter of all new cancer diagnoses for women in the U.S. (BreastCancer.Org, 2011). It ranks as the second leading cause of cancer-related mortality in women, accounting for nearly 40,000 estimated deaths in 2013 (American Cancer Society, 2011). <br> According to the National Cancer Institute's Surveillance Epidemiology and End Results program, the chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 30, it is one in 2,212. By age 40, the chances increase to one in 235, by age 50, it becomes one in 54, and, by age 60, it is one in 25. From 2004 to 2008, the median age at the time of breast cancer diagnosis was 61 years among adult women (Tangka et al, 2010). <br> In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits, and varying procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (Lavigne et al, 2008; Boykoff et al, 2009)."/> <clinicalRecommendationStatement value="The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years (B recommendation). The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C recommendation). The Task Force concludes the evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I statement). <br> U.S. Preventive Services Task Force (2009) <br> Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. <br> Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. <br> Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE). <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer."/> <improvementNotation value="increase"/> <guidance value="Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. <br> This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, MRIs or tomosynthesis (3D mammography), because they are not appropriate methods for primary breast cancer screening."/> <group> <identifier> <value value="group-1"/> </identifier> <population> <identifier> <value value="initial-population-identifier"/> </identifier> <code> <coding> <system value="http://terminology.hl7.org/CodeSystem/measure-population"/> <code value="initial-population"/> <display value="Initial Population"/> </coding> </code> <criteria value="Initial Population"/> </population> <population> <identifier> <value value="numerator-identifier"/> </identifier> <code> <coding> <system value="http://terminology.hl7.org/CodeSystem/measure-population"/> <code value="numerator"/> <display value="Numerator"/> </coding> </code> <criteria value="Numerator"/> </population> <population> <identifier> <value value="denominator-identifier"/> </identifier> <code> <coding> <system value="http://terminology.hl7.org/CodeSystem/measure-population"/> <code value="denominator"/> <display value="Denominator"/> </coding> </code> <criteria value="Denominator"/> </population> <population> <identifier> <value value="denominator-exclusions-identifier"/> </identifier> <code> <coding> <system value="http://terminology.hl7.org/CodeSystem/measure-population"/> <code value="denominator-exclusion"/> <display value="Denominator Exclusion"/> </coding> </code> <criteria value="Denominator Exclusion"/> </population> </group> <supplementalData> <identifier> <value value="sde-ethnicity"/> </identifier> <usage> <coding> <system value="http://hl7.org/fhir/measure-data-usage"/> <code value="supplemental-data"/> </coding> </usage> <criteria value="SDE Ethnicity"/> </supplementalData> <supplementalData> <identifier> <value value="sde-payer"/> </identifier> <usage> <coding> <system value="http://hl7.org/fhir/measure-data-usage"/> <code value="supplemental-data"/> </coding> </usage> <criteria value="SDE Payer"/> </supplementalData> <supplementalData> <identifier> <value value="sde-race"/> </identifier> <usage> <coding> <system value="http://hl7.org/fhir/measure-data-usage"/> <code value="supplemental-data"/> </coding> </usage> <criteria value="SDE Race"/> </supplementalData> <supplementalData> <identifier> <value value="sde-sex"/> </identifier> <usage> <coding> <system value="http://hl7.org/fhir/measure-data-usage"/> <code value="supplemental-data"/> </coding> </usage> <criteria value="SDE Sex"/> </supplementalData> </Measure>
© HL7.org (Clinical Quality Information WG). hl7.fhir.us.cqfmeasures#0.1.0 based on FHIR v3.0.1 generated 27/03/2019.
Links: Home
| QA Report | Search
| Version History
| 
| Propose a change